Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
234.90
+7.66 (3.37%)
After Hours: 234.90 0.00 (0.00%)
Aug 27, 6:38PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 228.40 - 236.02
52 week 111.41 - 263.81
Open 228.59
Vol / Avg. 1.82M/1.96M
Mkt cap 77.39B
P/E 96.56
Div/yield     -
EPS 2.43
Shares 341.19M
Beta 1.09
Inst. own 58%
Oct 19, 2015
Q3 2015 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 23, 2015
Q2 2015 Valeant Pharmaceuticals International Inc Earnings Release
Jul 23, 2015
Q2 2015 Valeant Pharmaceuticals International Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1.89% 11.04%
Operating margin 12.50% 23.11%
EBITD margin - 55.83%
Return on average assets -0.48% 3.36%
Return on average equity -3.30% 17.52%
Employees 16,800 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Officers and directors

J. Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Robert L. Rosiello Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager, Europe
Age: 64
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Bio & Compensation  - Reuters
Ari Kellen Executive Vice President, Company Group Chairman
Age: 51
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Bio & Compensation  - Reuters
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 39
Bio & Compensation  - Reuters
Robert A. Ingram Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
D. Robert Hale Director
Age: 30
Bio & Compensation  - Reuters
Howard Bradley Schiller Director
Age: 53
Bio & Compensation  - Reuters